sglt2i for evidence based cardiorenal protection in diabetic and non-diabetic chronic kidney disease
Published 1 year ago • 1.2K plays • Length 1:00:55Download video MP4
Download video MP3
Similar videos
-
38:03
addressing cardiorenal outcomes in ckd and t2d: what are the key considerations for daily practice?
-
9:06
sglt2 inhibitors in chronic kidney disease
-
18:34
expanding the range of kidney protection by sglt2i | beatriz fernandez fernandez, md, phd
-
1:06:58
e-seminar #1 new pharmacological therapies to slow the progression of diabetic kidney disease
-
16:24
how sglt2 inhibitors protect the kidney
-
56:01
ckd progression: interpreting guidelines through the lens of recent data; ckd and raasi optimisation
-
58:30
11-10-2022 - sglt2i: evidence and mechanisms for a nephrology-cardiology consensus
-
56:43
renal events in patients receiving neprilysin inhibitors: a systematic review and meta-analysis
-
35:40
efficacy and safety of zibotentan and dapagliflozin in patients with chronic kidney disease
-
35:24
professor david wheeler - 'how do sglt2 inhibitors benefit the kidney?'
-
6:11
dapa-ckd: does confirmed renoprotection make the case for first-line sglt2 inhibition? | luigi gnudi
-
1:04:03
sglt2i, glip-1a and mra in cardiorenal protection | monique cho
-
58:16
evidence based reduction of cardiovascular & renal outcomes in diabetes
-
30:38
the impact of glp-1ra and sglt2i on ckd progression in subjects with diabetes | peter rossing, md
-
28:56
christine limonte, md - update on sglt2i: real-world use and special population
-
1:02:19
cardiovascular, renal and metabolic benefits of sglt2i for type 2 diabetes and heart failure
-
54:06
social determinants of health, the transition from advanced chronic kidney disease to kidney failure
-
0:58
do sglt2 inhibitors protect the kidneys in non-diabetic patients? #meded #medicine #medicaleducation
-
22:27
ep 44 – latest thinking and evidence on chronic kidney disease